Enrollment completed across 18 clinical sites with 40+ investigators in the US, Canada, and New Zealand If the GPX ...
Fluidx Medical Technology, Inc. announced the completion of patient enrollment in the investigational device exemption (IDE) piv ...
As part of an ongoing multi-center study, Fluidx Medical released additional information on treating tumors including a highly vascularized metastatic renal cell carcinoma with the GPX Embolic Device.
SALT LAKE CITY, Jan. 20, 2022 /PRNewswire/ -- Fluidx Medical's GPX Embolic Device was used to effectively devascularize a large tumor with multiple feeding vessels as part of a multi-center clinical ...
SALT LAKE CITY, March 9, 2022 /PRNewswire/ -- As part of an ongoing multi-center study, Fluidx Medical released additional information on treating tumors including a highly vascularized metastatic ...
SALT LAKE CITY, Jan. 20, 2022 /PRNewswire/ -- Fluidx Medical's GPX Embolic Device was used to effectively devascularize a large tumor with multiple feeding vessels as part of a multi-center clinical ...
SALT LAKE CITY, March 9, 2022 /PRNewswire/ -- As part of an ongoing multi-center study, Fluidx Medical released additional information on treating tumors including a highly vascularized metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback